Skip to content
naulon
Not checkedNot checked for notices yet.

A review on risk assessment of formulation development and technology transfer of COVID-19 vaccines

Hari v, GNK Ganesh, Vivek Reddy M and 1 more

Vitae · 2022

doi:10.17533/udea.vitae.v29n2a348750 (opens in a new tab)

We email you when a new notice or a question about this paper appears.

Abstract

BACKGROUND: COVID-19 pandemic situation made the pharmaceutical companies develop the vaccine with different formulations in a short period. OBJECTIVES: The main objective of the review is to focus on different types of vaccine formulations available globally and the importance of technology transfer in vaccine development associated with potential risks. RESULTS: Research on vaccine development led to various types of vaccines, such as Inactivated vaccines, live attenuated vaccines, Ribonucleic acid (RNA) and Deoxyribonucleic acid (DNA) vaccines, viral vector vaccines, and Protein Subunit Vaccines for COVID-19. But the process of vaccine development and technology transfer is lined with various risks and challenges. Through risk assessment, we found some major potential risks involved in product development; this leads to a smoother and more efficient method to develop safe vaccines available for public health. CONCLUSIONS: This review will explain the significance of technology collaboration for the faster development of various formulations of vaccines globally.

Abstract licence: CC BY-NC-SA

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.